Welcome to the International Journal of Pharmacology, a key publication in the field of pharmacology, published by ASIAN NETWORK SCIENTIFIC INFORMATION (ANSINET). Since its inception in 2006, this journal has provided a vital platform for researchers and professionals to disseminate their findings and insights in pharmacology, toxicology, and pharmaceutics. Despite recent discontinuation in Scopus coverage, the journal's dedication to fostering scientific dialogue continues to attract contributions from esteemed scholars globally. With an **ISSN of 1811-7775** and **E-ISSN of 1812-5700**, the journal seeks to bridge the gap between laboratory research and clinical application, promoting a deeper understanding of drug actions and interactions. Although it operates under traditional access options, the relevance of its published studies to ongoing pharmacological research remains significant.

CLINICAL PHARMACOKINETICS, published by ADIS INT LTD, is a premier journal dedicated to the field of pharmacology, with a distinguished reputation since its inception in 1976. With an impressive impact factor and categorized in the Q1 quartile for both general pharmacology and medical pharmacology, this journal ranks #29 out of 272 and #53 out of 313 in its respective categories in Scopus, highlighting its high academic influence and the quality of research it publishes. CLINICAL PHARMACOKINETICS serves as a vital resource for researchers, professionals, and students interested in the latest advancements in drug metabolism, therapeutic efficacy, and clinical applications of pharmacokinetic studies. As it continues to evolve through 2024 and beyond, the journal remains committed to fostering a deeper understanding of pharmacotherapy and its implications in clinical practice. While it does not currently offer open access, the journal ensures that cutting-edge research is accessible through various academic platforms.

XENOBIOTICA is a premier journal in the field of pharmacology and toxicology, published by Taylor & Francis Ltd. With an ISSN of 0049-8254 and E-ISSN 1366-5928, this journal has been at the forefront of research since 1971, providing critical insights and advancements up until 2024. It is recognized for its rigorous peer-reviewed content, occupying a third quartile ranking across various categories including Biochemistry, Health, Toxicology, and Pharmacology as of 2023. The journal serves as a pivotal platform for disseminating innovative findings that address the impact of xenobiotics on health and the environment, making it an essential resource for researchers, professionals, and students engaged in these multidisciplinary fields. While it does not currently offer open access, it is widely respected for its contribution to science, evidenced by its Scopus rankings across different areas of study. The journal encourages submissions that push the boundaries of knowledge and transform our understanding of the effects of chemical substances on living organisms.

The European Journal of Pharmaceutical Sciences is a prestigious academic journal dedicated to advancing the field of pharmaceutical science. Published by Elsevier, the journal boasts an impressive impact factor and is categorized in the Q1 quartile for pharmaceutical science as of 2023, signifying its influence and reputation within the academic community. With a Scopus ranking of #20 out of 183 in the fields of pharmacology, toxicology, and pharmaceutics, the journal provides a vital platform for researchers and practitioners to disseminate innovative studies and groundbreaking research that push the boundaries of drug development and delivery. Based in the Netherlands and operating since 1993, the journal seeks to cover a broad scope of topics related to pharmaceutical sciences, encouraging rigorous evaluations and discussions that enhance the understanding and application of this critical field. The absence of open access underscores the commitment to maintaining high scholarly standards, while still offering avenues for libraries and institutions to provide access to cutting-edge research. As the journal converges towards its 2024 milestones, it continuously aims to foster a vibrant exchange of knowledge among its diverse readership, comprising committed researchers, professionals, and students.

SCIENTIA PHARMACEUTICA, published by MDPI in Switzerland, is a leading open access journal dedicated to advancing the field of pharmaceutical sciences since 2006. With a focus on pharmacology, toxicology, and pharmaceutics, this journal plays a pivotal role in disseminating high-quality research and innovative findings. It boasts an impressive impact factor and is ranked in the second quartile (Q2) for Pharmaceutical Science, signifying its influence within the academic community, aided by a Scopus ranking of 74 out of 183 journals in the same category. SCIENTIA PHARMACEUTICA invites original research articles, reviews, and notes that contribute to the understanding and development of pharmaceutical science, making it an essential resource for researchers, professionals, and students alike seeking to stay at the forefront of this continuously evolving field. For those interested in broadening their knowledge and sharing insights, the journal ensures wide accessibility, supporting the open access model for maximum outreach.

BIOPHARMACEUTICS & DRUG DISPOSITION, published by WILEY, is a prominent journal in the fields of biopharmaceutics and pharmacology, dedicated to the dissemination of vital research that spans from the foundational aspects of drug disposition to advanced therapeutic developments. Since its inception in 1979, this journal has established itself as a crucial resource for a diverse audience, including researchers, professionals, and students. With its impact factor indicating solid performance and a current ranking in Q2 for Pharmaceutical Science and Q3 across miscellaneous medicine categories, BIOPHARMACEUTICS & DRUG DISPOSITION serves as a nexus for innovative studies and breakthrough findings. The journal's comprehensive scope ensures that rigorous scientific inquiry is represented, helping to advance the understanding of drug behavior in biological systems. Participating in this scholarly dialogue not only enhances individual knowledge but contributes to the broader pharmaceutical and medical communities, making it an essential publication for all stakeholders interested in drug development and utilization.

Journal of Pharmaceutical Analysis is a premier open-access journal published by ELSEVIER, dedicated to advancing the field of pharmaceutical sciences. Since its inception in 2011, this journal has become a vital resource for researchers, professionals, and students, with a focus on analytical chemistry, drug discovery, and electrochemistry, among other subjects. With an impressive impact factor reflected in its Q1 ranking across multiple categories such as Analytical Chemistry and Drug Discovery in 2023, it maintains a high standard in the dissemination of innovative research. The journal not only facilitates the sharing of significant findings but also promotes collaboration and discussion within the community, making a notable impact globally. Articles published in the Journal of Pharmaceutical Analysis are easily accessible under an open-access model, ensuring that cutting-edge research reaches a diverse audience and enhances knowledge in this critical field. As it continues to converge research from 2011 to 2024, the journal remains a cornerstone in the study of pharmaceutical evaluation, analytical methods, and their applications.

CURRENT DRUG METABOLISM, published by Bentham Science Publishers Ltd, serves as a pivotal resource in the fields of Clinical Biochemistry and Pharmacology. With an ISSN of 1389-2002 and an E-ISSN of 1875-5453, this journal has carved a niche since its inception in 2000, offering in-depth research and reviews that bridge the gap between drug metabolism and its clinical applications. The journal finds itself positioned in the third quartile (Q3) for both Clinical Biochemistry and Pharmacology as of 2023, reflecting its significance within these scientific sectors, with Scopus rankings showcasing its role in advancing knowledge—rank #167 in Pharmacology and #66 in Clinical Biochemistry. Researchers and industry professionals are encouraged to contribute their findings, fostering a diverse platform that informs and inspires innovations in drug development and safety. While CURRENT DRUG METABOLISM operates under a traditional subscription model without open access, its rigorous peer-review process ensures the quality and integrity of the published work, making it indispensable for anyone engaged in drug research and biochemistry.

Drug Metabolism and Pharmacokinetics is a premier academic journal committed to advancing the understanding of drug metabolism processes and pharmacokinetic principles critical to the development of therapeutics. Published by the Japanese Society for the Study of Xenobiotics, this journal has established itself as a vital resource within Pharmaceutical Science and Pharmacology, achieving a respectable Q2 ranking in the latest 2023 metrics. Spanning from 2002 to 2024, the journal publishes original research articles, reviews, and insights that address contemporary issues in xenobiotic metabolism and pharmacologic practices. With its ISSN of 1347-4367 and E-ISSN of 1880-0920, Drug Metabolism and Pharmacokinetics is indexed in leading databases, enhancing its visibility and accessibility for researchers, professionals, and students alike. By fostering a rigorous scientific dialogue, the journal plays an essential role in shaping the future of pharmacology and pharmaceutical sciences.

Welcome to BMC Pharmacology & Toxicology, a premier open-access journal dedicated to advancing the fields of pharmacology and toxicology. Published by BMC since 2012, this esteemed journal offers a platform for researchers, professionals, and students to disseminate cutting-edge research and innovative findings that explore the intricate interactions between drugs and biological systems. With its robust Q2 ranking in both general medicine and pharmacology categories for 2023, BMC Pharmacology & Toxicology is recognized for its significant contributions to the academic community, reflected in its strategic positioning within the 61st and 49th percentiles in Scopus rankings for related disciplines. The journal's commitment to open access ensures that vital research is accessible to a global audience, fostering collaboration and informed discussions. We invite you to engage with the latest studies, reviews, and innovative methodologies that shape the future of pharmacological and toxicological sciences.